Abstract
Currently, schizophrenia, as a serious psychiatric disorder, continues affecting the quality of life in the psychotics. This disease is often debilitating and chronic, showing broad symptoms at one end by hallucinations, delusions, thought disorder and the other end by affective flattening, catatonia, social isolation. In order to combat this disease, many antipsychotic drugs have been developed and introduced into clinical practice in the past half century. However, only a small minority of them can treat effectively schizophrenia without side effects. In view of this situation, high attention has been given to the exploration of desired antipsychotic agents influential especially through the modulation of dopamine and serotonin receptors with substantial strides made in recent years, leading to the discovery of many novel chemical entities with intriguing profiles. In this review, we summarize novel structural antipsychotics in development and discuss the future direction of ideal antipsychotic drug candiates. In particular, the promising atypical antipsychotic profiles of new molecules and the inspirations for their design are highlighted.
Keywords: Arylpiperazines, atypical antipsychotics, butyrophenones, dopamine and serotonin receptors, schizophrenia, tricycles.
Current Drug Targets
Title:Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Volume: 14 Issue: 8
Author(s): Xin Li and Shutao Ma
Affiliation:
Keywords: Arylpiperazines, atypical antipsychotics, butyrophenones, dopamine and serotonin receptors, schizophrenia, tricycles.
Abstract: Currently, schizophrenia, as a serious psychiatric disorder, continues affecting the quality of life in the psychotics. This disease is often debilitating and chronic, showing broad symptoms at one end by hallucinations, delusions, thought disorder and the other end by affective flattening, catatonia, social isolation. In order to combat this disease, many antipsychotic drugs have been developed and introduced into clinical practice in the past half century. However, only a small minority of them can treat effectively schizophrenia without side effects. In view of this situation, high attention has been given to the exploration of desired antipsychotic agents influential especially through the modulation of dopamine and serotonin receptors with substantial strides made in recent years, leading to the discovery of many novel chemical entities with intriguing profiles. In this review, we summarize novel structural antipsychotics in development and discuss the future direction of ideal antipsychotic drug candiates. In particular, the promising atypical antipsychotic profiles of new molecules and the inspirations for their design are highlighted.
Export Options
About this article
Cite this article as:
Li Xin and Ma Shutao, Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors, Current Drug Targets 2013; 14 (8) . https://dx.doi.org/10.2174/13894501113149990007
DOI https://dx.doi.org/10.2174/13894501113149990007 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research HIV-1 RT Nonnucleoside Inhibitors and Their Interaction with RT for Antiviral Drug Development
Infectious Disorders - Drug Targets Lipid Membranes and β-Amyloid: A Harmful Connection
Current Protein & Peptide Science Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry Neurocognitive Correlates in Driving Under the Influence of <I>Cannabis</i>
CNS & Neurological Disorders - Drug Targets Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis
Current Pharmaceutical Design State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry The Psychoactive Effects of Antidepressants and their Association with Suicidality
Current Drug Safety P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Microwave Accelerated Labeling Methods in the Synthesis of Radioligands for Positron Emission Tomography Imaging
Current Radiopharmaceuticals “Bedside-to-Bench” Behavioral Outcomes in Animal Models of Pain: Beyond the Evaluation of Reflexes
Current Neuropharmacology Therapeutics and Carriers: The Dual Role of Proteins in Nanoparticles for Ocular Delivery
Current Topics in Medicinal Chemistry HDL Apolipoprotein-Related Peptides in the Treatment of Atherosclerosis and other Inflammatory Disorders
Current Pharmaceutical Design Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry The Risk That DSM-5 Will Further Inflate the Diagnostic Bubble
Current Psychiatry Reviews Structural Studies of the Klentaq1 DNA Polymerase
Current Organic Chemistry Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Genome-Wide Expression Analysis in Epilepsy: A Synthetic Review
Current Topics in Medicinal Chemistry Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry